We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Study Proves RFID Technology Safe for Use with Biologics
Product News

Study Proves RFID Technology Safe for Use with Biologics

Study Proves RFID Technology Safe for Use with Biologics
Product News

Study Proves RFID Technology Safe for Use with Biologics

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Study Proves RFID Technology Safe for Use with Biologics"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Intelleflex supports the findings of a study published by the Parenteral Drug Association (PDA) that RFID technology is both safe and suitable for use in the presence of biologics.

The study, “Effects of Radio Frequency Identification-related Radiation on In Vitro Biologics,” was conducted by researchers at The University of South Florida, Blood Center of Wisconsin, Abbott, Georgia Institute of Technology and the Madison RFID Lab at the University of Wisconsin and was published in the July-August edition of the PDA Journal of Pharmaceutical Science and Technology.

The report noted that RFID-based equipment could be used safely in close proximity to biologics, making the technology suitable for “track and trace” operations.

The research showed that in vitro test results for more than 100 biopharmaceutical products from eight major drug companies demonstrated no non-thermal effect by radio frequency radiation.

The findings come in advance of forthcoming requirements mandated by ePedigree laws in California and Florida, which are expected to go into effect in 2015 and ultimately impact the entire pharmaceutical industry.

Compliance with such laws will require a combination of RFID and 2D barcode technologies for monitoring the condition, authenticity and traceability of pharmaceuticals, including biologics.

Temperature-monitoring RFID technology is critical to an accurate assessment of the condition of biologics, such as vaccines, medications and therapeutics, which are typically highly temperature sensitive and require constant monitoring to verify adherence to distribution protocols that ensure safety, quality and efficacy.

“We’re pleased that the results of this study prove that RFID technology is inherently safe when used with biologics,” said Peter Mehring, President and CEO of Intelleflex.

Mehring continued, “By using RFID for package-level temperature monitoring, producers of biologics can not only take preventive action to safeguard their products during shipping, warehousing, and delivery, but can also maintain end-to-end traceability of those products to address pending ePedigree and serialization requirements, all helping to ensure patient safety.”